Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00573495 | Multipeptide Vaccine for Advanced Breast Cancer | completed | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01829971 |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection |
| terminated |
| Phase 1 |
| 155 |
| Mirna Therapeutics, Inc.INDUSTRY |
| 2 |
| Sep 27, 2016 |
| clinicaltrials |
| NCT00201734 | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary | terminated | Phase 1 / Phase 2 | 57 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 23, 2016 | clinicaltrials |
| NCT01283048 | Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 1 | 32 | Toni Choueiri, MDOTHER | 1 | Sep 21, 2016 | clinicaltrials |
| NCT00846131 | Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma | completed | Phase 1 | 24 | Northwestern UniversityOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02882659 | Dendritic Killer Cell-based Immunotherapy for Solid Tumors | unknown | Phase 1 | 18 | FullHope Biomedical Co., Ltd.INDUSTRY | 0 | Aug 30, 2016 | clinicaltrials |
| NCT00507091 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 25, 2016 | clinicaltrials |
| NCT01733004 | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Merrimack PharmaceuticalsINDUSTRY | 2 | Aug 4, 2016 | clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT02399735 | Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation | unknown | Phase 1 | 18 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT02787915 | DC1s-CTL Cellular Therapy for Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Xuzhou Medical UniversityOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01202032 | Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors(PARASOL) | completed | Phase 1 | 36 | Centre Leon BerardOTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT01778920 | Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA) | completed | Phase 1 | 48 | University of PennsylvaniaOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02772029 | A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT01008566 | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | May 12, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01219790 | ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma(GEMO) | completed | Phase 1 | 30 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 19, 2016 | clinicaltrials |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | unknown | Phase 1 | 112 | e-Therapeutics PLCINDUSTRY | 4 | Apr 6, 2016 | clinicaltrials |
| NCT02727309 | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | unknown | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02586285 | Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma | unknown | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02587884 | Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH | unknown | Phase 1 | 180 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724332 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | completed | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01497821 | AMG 172 First in Human Study in Patients With Kidney Cancer | completed | Phase 1 | 37 | AmgenINDUSTRY | 3 | Mar 25, 2016 | clinicaltrials |
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT00448149 | Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer | completed | Phase 1 / Phase 2 | 55 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00522249 | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | terminated | Phase 1 / Phase 2 | 10 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01276496 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01274455 | Gene Therapy of Pancreatic Ductal Adenocarcinoma(TherGAP) | completed | Phase 1 | 22 | University Hospital, ToulouseOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT02210182 | A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma | completed | Phase 1 | 29 | Oncozyme Pharma Inc.INDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01147380 | Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation(MIAMINK) | completed | Phase 1 | 18 | Seigo NishidaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02101593 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT00375310 | Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 | 27 | Indiana UniversityOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT02691871 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR | unknown | Phase 1 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT01924156 | DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02470559 | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 17, 2016 | clinicaltrials |
| NCT01594125 | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00324870 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT02403544 | Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma | unknown | Phase 1 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT02632006 | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02638857 | Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT00574977 | Safety Study of Modified Vaccinia Virus to Cancer | completed | Phase 1 | 26 | David BartlettOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT02133079 | Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 | unknown | Phase 1 / Phase 2 | 20 | Cure&Sure Biotech Co., LTDINDUSTRY | 1 | Dec 11, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Oct 4, 2016source: clinicaltrials